PhRMA Chief Medical Officer and Executive Vice President William Chin
Dr. William W. Chin is the Chief Medical Officer and Executive Vice President at PhRMA beginning in July 2013. He leads the association’s continuing efforts in science advocacy in the drug discovery and development ecosystem.
James M. (Mit) Spears is Executive Vice President and General Counsel of the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Spears oversees the Legal Department and also serves as a member of the PhRMA Management Committee.
Lori M. Reilly is Vice-President for Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Her primary focus is overseeing development of legislative and policy analysis and research studies on a range of health care issues.
Paul Aines is Executive Vice President, Administration, and Chief Financial Officer at PhRMA. He is responsible for budgeting and finance operations, IT services, human resources, facilities and Rx Response.
Chester “Chip” Davis, Jr. is the Executive Vice President for Advocacy and Member Relations at PhRMA. He leads PhRMA’s federal, state and international government relations and advocacy efforts, and is responsible for membership recruitment and retention.
Nelson Mandela once said, “Education is the most powerful weapon which you can use to change the world.” This statement couldn't be more accurate. With scientists and researchers in the biopharmaceutical industry constantly learning about diseases and working toward discovering new treatments for patients that could have a profound impact on our society, it is increasingly important to ensure we’re also developing the next generation of scientists.
Salvatore (“Salvo”) Alesci, M.D., Ph.D. joined PhRMA in December 2011 as Vice President, Scientific Affairs. In this role, Dr. Alesci serves as the primary expert for PhRMA on scientific and medical issues. He carries overall responsibility for establishing PhRMA as a “go to” source for input on policies and legislation related to innovative approaches to biopharmaceutical discovery and development. Dr.